Matrix Metalloproteinase Inhibitors
"Matrix Metalloproteinase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that inhibit the enzyme activity or activation of MATRIX METALLOPROTEINASES.
| Descriptor ID |
D061965
|
| MeSH Number(s) |
D27.505.519.389.745.610
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Matrix Metalloproteinase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Matrix Metalloproteinase Inhibitors".
This graph shows the total number of publications written about "Matrix Metalloproteinase Inhibitors" by people in this website by year, and whether "Matrix Metalloproteinase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 1 | 2 |
| 2003 | 0 | 3 | 3 |
| 2005 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2008 | 0 | 2 | 2 |
| 2009 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Matrix Metalloproteinase Inhibitors" by people in Profiles.
-
Effects of selective MMP-13 inhibition in squamous cell carcinoma depend on estrogen. Int J Cancer. 2014 Dec 15; 135(12):2749-59.
-
Modulation of matrix metalloproteinase activity in human thyroid cancer cell lines using demethylating agents and histone deacetylase inhibitors. Surgery. 2011 Apr; 149(4):504-11.
-
MMP-2 functions as an early response protein in ovarian cancer metastasis. Cell Cycle. 2009 Mar 01; 8(5):683-8.
-
The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J Clin Invest. 2008 Apr; 118(4):1367-79.
-
Molecular profiling of angiogenesis with targeted ultrasound imaging: early assessment of antiangiogenic therapy effects. Mol Cancer Ther. 2008 Jan; 7(1):101-9.
-
A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases. Clin Cancer Res. 2006 Mar 01; 12(5):1556-63.
-
Angiogenesis inhibition by vascular endothelial growth factor receptor-2 blockade reduces stromal matrix metalloproteinase expression, normalizes stromal tissue, and reverts epithelial tumor phenotype in surface heterotransplants. Cancer Res. 2005 Feb 15; 65(4):1294-305.
-
A phase I study of oral BMS-275291, a novel nonhydroxamate sheddase-sparing matrix metalloproteinase inhibitor, in patients with advanced or metastatic cancer. Clin Cancer Res. 2004 Mar 15; 10(6):1963-70.
-
Minocycline inhibits smooth muscle cell proliferation, migration and neointima formation after arterial injury. J Cardiovasc Pharmacol. 2003 Oct; 42(4):469-76.
-
Plasma matrix metalloproteinase 9 as biomarker of prostate cancer progression in Dunning (Copenhagen) rats. Prostate. 2003 Feb 15; 54(3):206-11.